Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)

Coleman, D. Jackson; Lee, Winston; Daly, Suzanne; Breazzano, Mark P.; Sparrow, Janet R.; Tsang, Stephen H.

doi:10.1016/j.ajoc.2020.100998

Cited by 2 publications

(2 citation statements)

References 22 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a study by Breazzano et al in 4 patients with chronic CSCR showed that treatment with sildenafil 40–80 mg twice a daily resolved the subretinal fluid and improved the visual acuity in 2 patients. Moreover, Coleman et al observed that discontinuation of PDE-5 inhibitor determined a recurrence of serous detachment in a patient successfully treated with sildenafil 60 mg daily [ 17 , 18 ]. See Table 2 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chronic Central Serous Chorioretinopathy with Pigment Epithelium Detachment Treated with Sildenafil: A Case Report

Finzi

Valsecchi

Tassi

et al. 2022

Case Rep Ophthalmol

View full text Add to dashboard Cite

Central serous chorioretinopathy (CSCR) is a retinal disease that may be complicated by the development of serous retinal pigment epithelial detachment (PED). The exact molecular mechanisms of CSCR have remained uncertain as well as there is no effective medical therapy. Herein, we describe a case of a 43-year-old male suffering from chronic CSCR with PED and visual acuity reduction (20/40) that showed improvement in visual acuity (20/25) and metamorphopsia 2 weeks after daily intake of 20 mg sildenafil tablets. Optical coherence tomography (OCT) scan showed resolution of PED with residual degeneration of the photoreceptor inner and outer segment layer and retinal pigmented epithelium. The patient continued treatment with sildenafil 20 mg for 2 months. Six months after the discontinuation of therapy, visual acuity was maintained, with absence of PED at OCT. Our case supports the hypothesis that phosphodiesterase type 5 (PDE-5) inhibitors may be an alternative in the treatment of patients with CSCR, alone or combined with other medications.

show abstract

Section: Discussionmentioning

confidence: 99%

“…PDE-5 inhibitors are a class of drugs used in erectile dysfunction, lower urinary symptoms, and pulmonary hypertension [10]. Previous studies have hypothesized that sildenafil intake could increase the risk of developing CSCR [11][12][13][14][15] (Table 1); however, a study by French et [17,18]. See Table 2.…”

Section: Discussionmentioning

confidence: 99%